disufenton sodium has been researched along with Acute Disease in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (88.89) | 29.6817 |
| 2010's | 2 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, CH; Du, X; Ewert, D; Floyd, R; Hu, N; Kopke, RD; Li, W; West, MB | 1 |
| Benatar, M; Fisher, M; Philip, M; Savitz, SI | 1 |
| Arba, F; Balami, JS; Buchan, AM; Kleinschnitz, C; Minnerup, J; Sutherland, BA | 1 |
| Jauch, EC; Wagner, KR | 1 |
| Boysen, G | 1 |
| Ashwood, T; Davalos, A; Davis, SM; Diener, HC; Grotta, J; Hårdemark, HG; Lees, KR; Lyden, P; Shuaib, A; Wasiewski, WW; Zivin, JA | 1 |
| Fong, JJ; Rhoney, DH | 1 |
| Doggrell, SA | 1 |
| Serebruany, V | 1 |
| Koziol, JA | 1 |
| Feng, AC; Koziol, JA | 1 |
| Hill, MD | 1 |
| Ahlberg, G; Ashwood, TJ; Davalos, A; Davis, SM; Diener, HC; Grotta, JC; Hardemark, HG; Lees, KR; Lyden, PD; Rodichok, L; Shuaib, A; Svensson, HH; Wasiewski, WW | 1 |
| Ashwood, T; Davalos, A; Davis, SM; Diener, HC; Emeribe, U; Grotta, J; Lees, KR; Lyden, P; Shuaib, A; Wasiewski, WW | 1 |
| Proctor, PH; Tamborello, LP | 1 |
| Fisher, M; Savitz, SI | 1 |
| Savitz, SI; Schäbitz, WR | 1 |
| Chacon, MR; Jensen, MB; Sattin, JA; Zivin, JA | 1 |
7 review(s) available for disufenton sodium and Acute Disease
| Article | Year |
|---|---|
Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials.
Topics: Acute Disease; Animals; Benzenesulfonates; Brain Ischemia; Cardiovascular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Models, Animal; Humans; Neuroprotective Agents; Research; Research Design; Risk; Stroke | 2009 |
Neuroprotection for ischaemic stroke: translation from the bench to the bedside.
Topics: Acute Disease; Animals; Benzenesulfonates; Brain Ischemia; Chelating Agents; Clinical Trials as Topic; Combined Modality Therapy; Diffusion of Innovation; Disease Models, Animal; Drug Evaluation, Preclinical; Egtazic Acid; Hematopoietic Cell Growth Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypothermia, Induced; Magnesium; Minocycline; NADPH Oxidases; Neuroprotective Agents; Pregnatrienes; Serum Albumin; Stroke; Thrombolytic Therapy; Translational Research, Biomedical | 2012 |
NXY-059: review of neuroprotective potential for acute stroke.
Topics: Acute Disease; Animals; Benzenesulfonates; Clinical Trials as Topic; Contraindications; Drug Interactions; Humans; Neuroprotective Agents; Nitrogen Oxides; Stroke | 2006 |
Is NXY-059 an advancement in the treatment of acute ischaemic stroke?
Topics: Acute Disease; Animals; Benzenesulfonates; Brain Ischemia; Cardiovascular Agents; Humans; Nitrogen Oxides; Stroke | 2006 |
On the analysis and interpretation of outcome measures in stroke clinical trials: lessons from the SAINT I study of NXY-059 for acute ischemic stroke.
Topics: Acute Disease; Benzenesulfonates; Biomarkers; Brain Damage, Chronic; Brain Ischemia; Cardiovascular Agents; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Disability Evaluation; Double-Blind Method; Free Radical Scavengers; Humans; Neuroprotective Agents; Neuropsychological Tests; Nitrogen Oxides; Randomized Controlled Trials as Topic; Sample Size; Severity of Illness Index; Statistics, Nonparametric; Stroke; Treatment Failure; Treatment Outcome | 2006 |
A Critique of SAINT II: wishful thinking, dashed hopes, and the future of neuroprotection for acute stroke.
Topics: Acute Disease; Benzenesulfonates; Clinical Trials as Topic; Humans; Neuroprotective Agents; Stroke; Treatment Failure | 2008 |
Neuroprotection in cerebral ischemia: emphasis on the SAINT trial.
Topics: Acute Disease; Benzenesulfonates; Brain Ischemia; Cardiovascular Agents; Clinical Trials as Topic; GABA Agonists; Humans; Hypothermia; N-Methylaspartate; Narcotic Antagonists; Neuroprotective Agents; Stroke; Tissue Plasminogen Activator | 2008 |
3 trial(s) available for disufenton sodium and Acute Disease
| Article | Year |
|---|---|
NXY-059 for acute ischemic stroke.
Topics: Acute Disease; Benzenesulfonates; Brain Ischemia; Cross-Over Studies; Disability Evaluation; Double-Blind Method; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Infusions, Intravenous; Nervous System Diseases; Neuroprotective Agents; Nitrogen Oxides; Severity of Illness Index; Stroke; Time Factors; Tissue Plasminogen Activator; Treatment Outcome | 2006 |
Safety and tolerability of NXY-059 for acute intracerebral hemorrhage: the CHANT Trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antioxidants; Benzenesulfonates; Brain; Cerebral Arteries; Cerebral Hemorrhage; Disability Evaluation; Double-Blind Method; Down-Regulation; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Male; Middle Aged; Placebos; Potassium; Time Factors; Treatment Outcome | 2007 |
NXY-059 for the treatment of acute ischemic stroke.
Topics: Acute Disease; Aged; Benzenesulfonates; Brain Ischemia; Cardiovascular Agents; Double-Blind Method; Female; Humans; Infusions, Intravenous; Male; Odds Ratio; Stroke; Time Factors; Treatment Failure | 2007 |
8 other study(ies) available for disufenton sodium and Acute Disease
| Article | Year |
|---|---|
HPN-07, a free radical spin trapping agent, protects against functional, cellular and electrophysiological changes in the cochlea induced by acute acoustic trauma.
Topics: Action Potentials; Acute Disease; Animals; Benzenesulfonates; Chinchilla; Cochlea; Female; Free Radical Scavengers; Wounds and Injuries | 2017 |
Extending the window for acute stroke treatment: thrombolytics plus CNS protective therapies.
Topics: Acute Disease; Animals; Benzenesulfonates; Central Nervous System; Cerebral Hemorrhage; Disease Models, Animal; Drug Therapy, Combination; Fibrinolytic Agents; Free Radical Scavengers; Humans; Hypothermia, Induced; Neuroprotective Agents; Nitrogen Oxides; Oxidative Stress; Stroke; Tenecteplase; Time Factors; Tissue Plasminogen Activator | 2004 |
[Follow up of a contribution about treatment of acute apoplexy].
Topics: Acute Disease; Benzenesulfonates; Humans; Neuroprotective Agents; Nitrogen Oxides; Stroke | 2005 |
NXY-059 for acute ischemic stroke.
Topics: Acute Disease; Benzenesulfonates; Brain Ischemia; Cardiovascular Agents; Data Interpretation, Statistical; Hemorrhage; Humans; Nitrogen Oxides; Stroke | 2006 |
NXY-059 for acute ischemic stroke.
Topics: Acute Disease; Benzenesulfonates; Brain Ischemia; Cardiovascular Agents; Data Interpretation, Statistical; Humans; Nitrogen Oxides; Stroke | 2006 |
Stroke: the dashed hopes of neuroprotection.
Topics: Acute Disease; Aspirin; Benzenesulfonates; Carotid Arteries; Clopidogrel; Dipyridamole; Europe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neuroprotective Agents; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stents; Stroke; Ticlopidine | 2007 |
SAINT-I worked, but the neuroprotectant is not NXY-059.
Topics: Acute Disease; Antioxidants; Benzenesulfonates; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Humans; Neuroprotective Agents; Stroke | 2007 |
NXY-059 for the treatment of stroke.
Topics: Acute Disease; Animals; Benzenesulfonates; Cardiovascular Agents; Drug Evaluation, Preclinical; Humans; Reproducibility of Results; Research Design; Stroke | 2007 |